Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1822290

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1822290

Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030

PUBLISHED:
PAGES: 367 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsTechnology, Stimulation Type, Application, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth.

Neuromodulation Market - IMG1

"The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period."

By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions.

"The internal neuromodulation accounted for the largest market share in the neuromodulation market."

The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice.

"The Asia Pacific is the fastest-growing region of the neuromodulation market by region."

The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30%
  • By Designation: C Level: 30%, Director Level: 34%, and Others: 36%
  • By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4%

Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US).

Research Coverage

This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries.

Reasons to Buy the Report

The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position.

This report provides insights into the following pointers:

  • Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
Show more
Product Code: BT 3571

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 List of key secondary sources
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key objectives of primary research
      • 2.1.2.2 List of primary sources
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Breakdown of primary interviews
      • 2.1.2.5 Insights from industry experts
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Revenue estimation of key players
      • 2.2.1.2 Study of annual reports and investor presentations
      • 2.2.1.3 Primary interviews
      • 2.2.1.4 Growth forecast
      • 2.2.1.5 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION
  • 2.4 STUDY ASSUMPTIONS
    • 2.4.1 RESEARCH-RELATED ASSUMPTIONS
    • 2.4.2 PARAMETRIC ASSUMPTIONS
    • 2.4.3 GROWTH-RATE ASSUMPTIONS
    • 2.4.4 MARKET ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS
  • 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET
  • 4.2 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024
  • 4.3 NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
  • 4.4 NEUROMODULATION MARKET: REGIONAL MIX

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
      • 5.2.1.2 High incidence of neurological disorders among geriatric population
      • 5.2.1.3 Favorable government support and funding with advanced healthcare infrastructure
      • 5.2.1.4 Development of advanced neuromodulation and neurostimulation technologies
      • 5.2.1.5 Growing collaborations among device manufacturers, healthcare providers, and research institutions
      • 5.2.1.6 Availability of reimbursements for neuromodulation devices
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of neuromodulation procedures
      • 5.2.2.2 Preference for drug therapies over neuromodulation products
      • 5.2.2.3 Adverse effects and complications with neuromodulation devices
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Large population and high healthcare expenditure in emerging economies
      • 5.2.3.2 Widening application scope of neuromodulation
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
      • 5.2.4.2 Shortage of trained professionals
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023-2025
    • 5.4.2 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023-2025
    • 5.4.3 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023-2025
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Transcutaneous electrical nerve stimulation
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Wearable biosensors
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Regenerative medicine and stem cells
  • 5.10 PATENT ANALYSIS
    • 5.10.1 LIST OF KEY PATENTS
  • 5.11 TRADE DATA ANALYSIS
    • 5.11.1 IMPORT DATA FOR HS CODE 901890
    • 5.11.2 EXPORT DATA FOR HS CODE 901890
  • 5.12 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.13 CASE STUDY ANALYSIS
    • 5.13.1 USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH, CLINICAL PRACTICE, AND CONSUMER APPLICATIONS
    • 5.13.2 PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS
    • 5.13.3 APPLICATION OF NEUROMODULATION TECHNIQUES-FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION
  • 5.14 REGULATORY ANALYSIS
    • 5.14.1 REGULATORY LANDSCAPE
      • 5.14.1.1 North America
        • 5.14.1.1.1 US
        • 5.14.1.1.2 Canada
      • 5.14.1.2 Europe
      • 5.14.1.3 Asia Pacific
        • 5.14.1.3.1 China
        • 5.14.1.3.2 Japan
        • 5.14.1.3.3 India
    • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 PORTER'S FIVE FORCES ANALYSIS
    • 5.15.1 BARGAINING POWER OF SUPPLIERS
    • 5.15.2 BARGAINING POWER OF BUYERS
    • 5.15.3 THREAT OF NEW ENTRANTS
    • 5.15.4 THREAT OF SUBSTITUTES
    • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.16.2 KEY BUYING CRITERIA
  • 5.17 IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET
    • 5.17.1 INTRODUCTION
    • 5.17.2 POTENTIAL OF AI
    • 5.17.3 IMPACT OF AI
    • 5.17.4 KEY COMPANIES IMPLEMENTING AI
    • 5.17.5 FUTURE OF AI
  • 5.18 IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET
    • 5.18.1 INTRODUCTION
    • 5.18.2 KEY TARIFF RATES
    • 5.18.3 PRICE IMPACT ANALYSIS
    • 5.18.4 IMPACT ON COUNTRY/REGION
      • 5.18.4.1 North America
      • 5.18.4.2 Europe
      • 5.18.4.3 Asia Pacific
    • 5.18.5 IMPACT ON END-USE INDUSTRIES
      • 5.18.5.1 Hospitals

6 NEUROMODULATION MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
  • 6.2 INTERNAL NEUROMODULATION
    • 6.2.1 INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT RESULTS AND LOWER HEALTHCARE COSTS
  • 6.3 EXTERNAL NEUROMODULATION
    • 6.3.1 RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL AND PAIN-RELATED DISORDERS TO FUEL GROWTH

7 NEUROMODULATION MARKET, BY STIMULATION TYPE

  • 7.1 INTRODUCTION
  • 7.2 SPINAL CORD STIMULATION
    • 7.2.1 GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH
  • 7.3 DEEP BRAIN STIMULATION
    • 7.3.1 MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS
  • 7.4 SACRAL NERVE STIMULATION
    • 7.4.1 INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH
  • 7.5 VAGUS NERVE STIMULATION
    • 7.5.1 RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY
  • 7.6 GASTRIC NERVE STIMULATION
    • 7.6.1 INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH
  • 7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION
    • 7.7.1 LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR
  • 7.8 TRANSCRANIAL MAGNETIC STIMULATION
    • 7.8.1 MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND
  • 7.9 RESPIRATORY ELECTRICAL STIMULATION
    • 7.9.1 HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH
  • 7.10 OTHER STIMULATION TYPES

8 NEUROMODULATION MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION
    • 8.2.1 CHRONIC PAIN
      • 8.2.1.1 High incidence of chronic pain among geriatric population to support market growth
    • 8.2.2 FAILED BACK SURGERY SYNDROME
      • 8.2.2.1 Increasing number of spinal surgeries to aid market growth
    • 8.2.3 ISCHEMIA
      • 8.2.3.1 High effectiveness of neuromodulation to boost effectiveness for ischemia treatment
  • 8.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION
    • 8.3.1 PARKINSON'S DISEASE
      • 8.3.1.1 Development of advanced solutions and increased R&D to improve market growth
    • 8.3.2 TREMORS
      • 8.3.2.1 Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market
    • 8.3.3 DEPRESSION
      • 8.3.3.1 Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment
    • 8.3.4 OTHER DEEP BRAIN STIMULATION APPLICATIONS
  • 8.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION
    • 8.4.1 URINE INCONTINENCE
      • 8.4.1.1 High incidence of urine incontinence to offer growth opportunities for market players
    • 8.4.2 FECAL INCONTINENCE
      • 8.4.2.1 Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence
  • 8.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION
    • 8.5.1 EPILEPSY
      • 8.5.1.1 Low risk with device implantation and long-lasting battery life to aid market growth
    • 8.5.2 OTHER VAGUS NERVE STIMULATION APPLICATIONS
  • 8.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
    • 8.6.1 GASTROPARESIS
      • 8.6.1.1 Reduced hospitalization time associated with sastroparesis treatment to augment market growth
    • 8.6.2 OBESITY
      • 8.6.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market growth
  • 8.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION
    • 8.7.1 TREATMENT-RESISTANT DEPRESSION
      • 8.7.1.1 High prevalence of chronic and recurrent depression to augment market growth
    • 8.7.2 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS
  • 8.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION
    • 8.8.1 DEPRESSION
      • 8.8.1.1 Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients
    • 8.8.2 MIGRAINE
      • 8.8.2.1 High prevalence of migraines to support market growth
  • 8.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION
    • 8.9.1 INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS
  • 8.10 OTHER APPLICATIONS

9 NEUROMODULATION MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS & AMBULATORY SURGERY CENTERS
    • 9.2.1 ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH
  • 9.3 CLINICS & PHYSIOTHERAPY CENTERS
    • 9.3.1 NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION
  • 9.4 OTHER END USERS

10 NEUROMODULATION MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American neuromodulation market during forecast period
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing neurological disorder rates and rising government funding to propel market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Advanced surgical innovations and favorable reimbursement policies to drive market
    • 10.3.3 FRANCE
      • 10.3.3.1 Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques
    • 10.3.4 UK
      • 10.3.4.1 Increased public & private sector healthcare expenditure and investments to fuel market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Rising cases of dementia and Alzheimer's among geriatric population to spur market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Favorable government-led healthcare initiatives to support market growth
    • 10.3.7 RUSSIA
      • 10.3.7.1 Shifting demographic landscape and escalating neurological health needs to drive demand
    • 10.3.8 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand
    • 10.4.3 JAPAN
      • 10.4.3.1 Innovative healthcare delivery and advanced infrastructure landscape to augment market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Increasing cases of depressive and post-traumatic stress disorders to propel market demand
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Improvements in healthcare infrastructure to aid market growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Expanding healthcare awareness and growing burden of neurological disorders to favor market growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET
  • 11.3 REVENUE ANALYSIS, 2020-2024
  • 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Technology footprint
      • 11.5.5.4 Stimulation type footprint
      • 11.5.5.5 End-user footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 11.6.5.1 Detailed list of key startups/SMEs
      • 11.6.5.2 Competitive benchmarking of startups/SMEs
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
    • 11.7.1 COMPANY VALUATION
    • 11.7.2 FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & APPROVALS
    • 11.9.2 DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 MEDTRONIC
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product approvals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 BOSTON SCIENTIFIC CORPORATION
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 ABBOTT
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches and approvals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 LIVANOVA PLC
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product launches
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Right to win
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses & competitive threats
    • 12.1.5 NEVRO CORP.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product approvals
        • 12.1.5.3.2 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Right to win
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses & competitive threats
    • 12.1.6 NEUROPACE, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
    • 12.1.7 BIOVENTUS
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Product approvals
    • 12.1.8 ELECTROCORE, INC.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product launches
        • 12.1.8.3.2 Deals
    • 12.1.9 HELIUS MEDICAL TECHNOLOGIES, INC.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Deals
    • 12.1.10 NEURONETICS
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product approvals
        • 12.1.10.3.2 Deals
  • 12.2 OTHER PLAYERS
    • 12.2.1 NEUROSIGMA, INC.
    • 12.2.2 SOTERIX MEDICAL INC.
    • 12.2.3 SYNAPSE BIOMEDICAL INC.
    • 12.2.4 ALEVA NEUROTHERAPEUTICS
    • 12.2.5 THERANICA BIO-ELECTRONICS LTD.
    • 12.2.6 GIMER MEDICAL
    • 12.2.7 NALU MEDICAL, INC.
    • 12.2.8 MICROTRANSPONDER INC.
    • 12.2.9 MAGSTIM
    • 12.2.10 AMBER THERAPEUTICS
    • 12.2.11 TVNS TECHNOLOGIES GMBH
    • 12.2.12 BIOWAVE
    • 12.2.13 BIOTRONIK
    • 12.2.14 SALUDA MEDICAL PTY LTD.
    • 12.2.15 SPR

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Show more
Product Code: BT 3571

List of Tables

  • TABLE 1 NEUROMODULATION MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 NEUROMODULATION MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 MARKET ASSUMPTIONS IN NEUROMODULATION MARKET
  • TABLE 4 RISK ANALYSIS IN NEUROMODULATION MARKET
  • TABLE 5 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES
  • TABLE 6 AVERAGE SELLING PRICING TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023-2025 (USD)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023-2025 (USD)
  • TABLE 9 ROLE OF KEY PLAYERS IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)
  • TABLE 10 LIST OF KEY PATENTS IN NEUROMODULATION MARKET, 2022-2025
  • TABLE 11 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020-2024 (USD MILLION)
  • TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN NEUROMODULATION MARKET, JANUARY 2025-DECEMBER 2026
  • TABLE 14 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
  • TABLE 15 NATIONAL MEDICAL PRODUCT ADMINISTRATION (NMPA) MEDICAL DEVICES CLASSIFICATION
  • TABLE 16 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 IMPACT OF PORTER'S FIVE FORCES ON NEUROMODULATION MARKET
  • TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
  • TABLE 24 KEY BUYING CRITERIA, BY END USER
  • TABLE 25 KEY COMPANIES IMPLEMENTING AI IN NEUROMODULATION MARKET
  • TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 27 NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 28 INTERNAL NEUROMODULATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 34 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 39 SPINAL CORD STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 40 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 41 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 DEEP BRAIN STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 46 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: NEUROMODULATION FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 50 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 SACRAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 52 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 53 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 VAGUS NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 58 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 59 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 GASTRIC NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 64 NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 EUROPE: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 70 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 TRANSCRANIAL MAGNETIC STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 76 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 77 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 RESPIRATORY ELECTRICAL STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 82 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 83 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 OTHER STIMULATION DEVICES OFFERED BY KEY PLAYERS
  • TABLE 88 NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 EUROPE: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 94 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 EUROPE: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 EUROPE: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 105 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 EUROPE: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 110 DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 EUROPE: DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 115 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 116 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 EUROPE: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 126 NORTH AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 EUROPE: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 LATIN AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 132 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 EUROPE: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 EUROPE: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 142 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 EUROPE: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 LATIN AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 148 NORTH AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 EUROPE: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 151 LATIN AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 153 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 154 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 GLOBAL NUMBERS OF ADULTS WITH OBESITY (BMI >=30 KG/M2 ), BY REGION (BILLION)
  • TABLE 159 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 160 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 165 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 LATIN AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 171 NORTH AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 EUROPE: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 LATIN AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 176 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 177 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 178 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 180 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 182 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 185 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 187 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 190 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 191 OTHER NEUROMODULATION APPLICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 192 NORTH AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 193 EUROPE: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 194 ASIA PACIFIC: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 195 LATIN AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 196 NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 197 NUMBER OF HOSPITALS PER CAPITA, BY COUNTRY, 2024
  • TABLE 198 NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 199 NORTH AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 200 EUROPE: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 LATIN AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 203 NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 204 NORTH AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 205 EUROPE: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: NEUROMODULATION FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 207 LATIN AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 208 NEUROMODULATION MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 209 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, 2023-2030 (USD MILLION)
  • TABLE 210 EUROPE: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 212 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 213 NEUROMODULATION MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 214 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 215 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 216 NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 217 NORTH AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 219 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 220 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 221 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 222 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 223 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 224 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 225 NORTH AMERICA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 226 US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 227 US: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 US: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 229 US: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 230 US: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 231 US: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 232 US: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 233 US: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 234 US: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 235 US: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 236 CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 237 CANADA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 238 CANADA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 239 CANADA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 240 CANADA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 241 CANADA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 242 CANADA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 243 CANADA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 244 CANADA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 245 CANADA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 246 EUROPE: KEY MACROINDICATORS
  • TABLE 247 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 248 EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 249 EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 251 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 252 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 253 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 254 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 255 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 256 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 257 EUROPE: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 258 GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 259 GERMANY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 260 GERMANY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 261 GERMANY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 262 GERMANY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 263 GERMANY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 264 GERMANY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 265 GERMANY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 266 GERMANY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 267 GERMANY: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 268 FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 269 FRANCE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 270 FRANCE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 271 FRANCE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 272 FRANCE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 273 FRANCE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 274 FRANCE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 275 FRANCE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 276 FRANCE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 277 FRANCE: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 278 UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 279 UK: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 280 UK: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 281 UK: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 282 UK: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 283 UK: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 284 UK: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 285 UK: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 286 UK: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 287 UK: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 288 ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 289 ITALY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 290 ITALY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 291 ITALY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 292 ITALY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 293 ITALY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 294 ITALY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 295 ITALY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 296 ITALY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 297 ITALY: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 298 SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 299 SPAIN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 300 SPAIN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 301 SPAIN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 302 SPAIN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 303 SPAIN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 304 SPAIN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 305 SPAIN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 306 SPAIN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 307 SPAIN: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 308 RUSSIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 309 RUSSIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 RUSSIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 311 RUSSIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 312 RUSSIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 313 RUSSIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 314 RUSSIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 315 RUSSIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 316 RUSSIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 317 RUSSIA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 318 REST OF EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 319 REST OF EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 REST OF EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 321 REST OF EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 322 REST OF EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 323 REST OF EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 324 REST OF EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 325 REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 326 REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 327 REST OF EUROPE: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 328 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 329 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 330 ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 331 ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 332 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 333 ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 334 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 335 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 336 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 337 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 338 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 339 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 340 CHINA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 341 CHINA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 342 CHINA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 343 CHINA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 344 CHINA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 345 CHINA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 346 CHINA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 347 CHINA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 348 CHINA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 349 CHINA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 350 JAPAN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 351 JAPAN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 352 JAPAN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 353 JAPAN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 354 JAPAN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 355 JAPAN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 356 JAPAN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 357 JAPAN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 358 JAPAN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 359 JAPAN: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 360 INDIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 361 INDIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 362 INDIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 363 INDIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 364 INDIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 365 INDIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 366 INDIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 367 INDIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 368 INDIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 369 INDIA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 370 AUSTRALIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 371 AUSTRALIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 372 AUSTRALIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 373 AUSTRALIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 374 AUSTRALIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 375 AUSTRALIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 376 AUSTRALIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 377 AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 378 AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 379 AUSTRALIA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 380 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 381 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 383 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 384 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 385 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 386 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 387 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 388 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 389 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 390 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 391 LATIN AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 392 LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 393 LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 394 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 395 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 396 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 397 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 398 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 399 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 400 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 401 LATIN AMERICA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 402 BRAZIL: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 403 BRAZIL: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 404 BRAZIL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 405 BRAZIL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 406 BRAZIL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 407 BRAZIL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 408 BRAZIL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 409 BRAZIL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 410 BRAZIL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 411 BRAZIL: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 412 MEXICO: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 413 MEXICO: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 414 MEXICO: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 415 MEXICO: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 416 MEXICO: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 417 MEXICO: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 418 MEXICO: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 419 MEXICO: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 420 MEXICO: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 421 MEXICO: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 422 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 423 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 424 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 425 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 426 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 427 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 428 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 429 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 430 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 431 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 432 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 433 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 434 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023-2030 (USD MILLION)
  • TABLE 435 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 436 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 437 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 438 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 439 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 440 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 441 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 442 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 443 MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NEUROMODULATION MARKET, JANUARY 2022-JULY 2025
  • TABLE 444 NEUROMODULATION MARKET: DEGREE OF COMPETITION
  • TABLE 445 NEUROMODULATION MARKET: REGION FOOTPRINT
  • TABLE 446 NEUROMODULATION MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 447 NEUROMODULATION MARKET: STIMULATION TYPE FOOTPRINT
  • TABLE 448 NEUROMODULATION MARKET: END-USER FOOTPRINT
  • TABLE 449 NEUROMODULATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 450 NEUROMODULATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TECHNOLOGY AND REGION
  • TABLE 451 NEUROMODULATION MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 452 NEUROMODULATION MARKET: DEALS, JANUARY 2022-JULY 2025
  • TABLE 453 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 454 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 455 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 456 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 457 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 458 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 459 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022-JULY 2025
  • TABLE 460 ABBOTT: COMPANY OVERVIEW
  • TABLE 461 ABBOTT: PRODUCTS OFFERED
  • TABLE 462 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 463 LIVANOVA PLC: COMPANY OVERVIEW
  • TABLE 464 LIVANOVA PLC: PRODUCTS OFFERED
  • TABLE 465 LIVANOVA PLC: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 466 NEVRO CORP.: COMPANY OVERVIEW
  • TABLE 467 NEVRO CORP.: PRODUCTS OFFERED
  • TABLE 468 NEVRO CORP.: PRODUCT APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 469 NEVRO CORP.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 470 NEUROPACE, INC.: COMPANY OVERVIEW
  • TABLE 471 NEUROPACE, INC.: PRODUCTS OFFERED
  • TABLE 472 BIOVENTUS: COMPANY OVERVIEW
  • TABLE 473 BIOVENTUS: PRODUCTS OFFERED
  • TABLE 474 BIOVENTUS: PRODUCT APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 475 ELECTROCORE, INC.: COMPANY OVERVIEW
  • TABLE 476 ELECTROCORE, INC.: PRODUCTS OFFERED
  • TABLE 477 ELECTROCORE, INC.: PRODUCT LAUNCHES, JANUARY 2022-JULY 2025
  • TABLE 478 ELECTROCORE, INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 479 HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 480 HELIUS MEDICAL TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • TABLE 481 HELIUS MEDICAL TECHNOLOGIES, INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 482 NEURONETICS: COMPANY OVERVIEW
  • TABLE 483 NEURONETICS: PRODUCTS OFFERED
  • TABLE 484 NEURONETICS: PRODUCT APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 485 NEURONETICS: DEALS, JANUARY 2022-JULY 2025
  • TABLE 486 NEUROSIGMA, INC.: COMPANY OVERVIEW
  • TABLE 487 SOTERIX MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 488 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW
  • TABLE 489 ALEVA NEUROTHERAPEUTICS: COMPANY OVERVIEW
  • TABLE 490 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW
  • TABLE 491 GIMER MEDICAL: COMPANY OVERVIEW
  • TABLE 492 NALU MEDICAL, INC.: COMPANY OVERVIEW
  • TABLE 493 MICROTRANSPONDER INC.: COMPANY OVERVIEW
  • TABLE 494 MAGSTIM: COMPANY OVERVIEW
  • TABLE 495 AMBER THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 496 TVNS TECHNOLOGIES GMBH: COMPANY OVERVIEW
  • TABLE 497 BIOWAVE: COMPANY OVERVIEW
  • TABLE 498 BIOTRONIK: COMPANY OVERVIEW
  • TABLE 499 SALUDA MEDICAL PTY LTD.: COMPANY OVERVIEW
  • TABLE 500 SPR: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 NEUROMODULATION MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 NEUROMODULATION MARKET: YEARS CONSIDERED
  • FIGURE 3 NEUROMODULATION MARKET: RESEARCH DESIGN
  • FIGURE 4 NEUROMODULATION MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 LIST OF PRIMARY SOURCES IN NEUROMODULATION MARKET
  • FIGURE 6 NEUROMODULATION MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7 KEY INSIGHTS FROM PRIMARY EXPERTS IN NEUROMODULATION MARKET
  • FIGURE 8 REVENUE ESTIMATION OF KEY PLAYERS IN NEUROMODULATION MARKET
  • FIGURE 9 CAGR PROJECTIONS INNEUROMODULATION MARKET
  • FIGURE 10 NEUROMODULATION MARKET: TOP-DOWN APPROACH
  • FIGURE 11 NEUROMODULATION MARKET: DATA TRIANGULATION
  • FIGURE 12 PARAMETRIC ASSUMPTIONS IN NEUROMODULATION MARKET
  • FIGURE 13 NEUROMODULATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 NEUROMODULATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 REGIONAL SNAPSHOT OF NEUROMODULATION MARKET
  • FIGURE 18 RISE IN GERIATRIC POPULATION AND HIGH DEMAND FOR ADVANCED NEUROMODULATION THERAPIES TO DRIVE MARKET
  • FIGURE 19 CHINA AND HOSPITALS & AMBULATORY SURGERY CENTERS COMMANDED SIGNIFICANT MARKET SHARES IN 2024
  • FIGURE 20 CHINA TO ACCOUNT FOR HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 21 ASIA PACIFIC TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD
  • FIGURE 22 NEUROMODULATION MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS IN NEURMODULATION MARKET
  • FIGURE 24 NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 NEUROMODULATION MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 26 NEUROMODULATION MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 FUNDING AND NUMBER OF DEALS IN NEUROMODULATION MARKET, 2021-2024 (USD MILLION)
  • FIGURE 28 NEUROMODULATION MARKET: TOP 10 PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS APPLIED/GRANTED, 2015-2024
  • FIGURE 29 NEUROMODULATION MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 31 KEY BUYING CRITERIA, BY END USER
  • FIGURE 32 IMPACT OF AI ON NEUROMODULATION MARKET
  • FIGURE 33 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 34 NUMBER OF PATIENTS WITH ALZHEIMER'S IN US, 2020-2060 (MILLION)
  • FIGURE 35 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET, 2020-2024 (USD MILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET (2024)
  • FIGURE 38 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 39 NEUROMODULATION MARKET: COMPANY FOOTPRINT
  • FIGURE 40 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 NEUROMODULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT
  • FIGURE 45 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 47 LIVANOVA PLC: COMPANY SNAPSHOT
  • FIGURE 48 NEVRO CORP.: COMPANY SNAPSHOT
  • FIGURE 49 NEUROPACE, INC.: COMPANY SNAPSHOT
  • FIGURE 50 BIOVENTUS: COMPANY SNAPSHOT
  • FIGURE 51 ELECTROCORE, INC.: COMPANY SNAPSHOT
  • FIGURE 52 HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 53 NEURONETICS: COMPANY SNAPSHOT
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!